Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43722   clinical trials with a EudraCT protocol, of which   7255   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2009-012057-38
    Sponsor's Protocol Code Number:CQTI571A2301
    National Competent Authority:Germany - BfArM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2009-06-10
    Trial results View results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedGermany - BfArM
    A.2EudraCT number2009-012057-38
    A.3Full title of the trial
    A 24-week randomized placebo-controlled, double-blind multi-center clinical trial evaluating the efficacy and safety of oral QTI571 as an add-on therapy in the treatment of severe pulmonary arterial hypertension: Imatinib in Pulmonary arterial hypertension, a Randomized, Efficacy Study
    A.3.2Name or abbreviated title of the trial where available
    A.4.1Sponsor's protocol code numberCQTI571A2301
    A.7Trial is part of a Paediatric Investigation Plan Information not present in EudraCT
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorNovartis Pharma Services AG
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisation
    B.5.2Functional name of contact point
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D. name Glivec® 100 mg Filmtabletten
    D. of the Marketing Authorisation holderNovartis Europharm Ltd
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code QTI571
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNImatinib mesilate
    D.3.9.1CAS number 220127-57-1
    D.3.9.2Current sponsor codeQTI571
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product Information not present in EudraCT
    D. ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D. on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Pulmonary arterial hypertension (PAH) patients who have a PVR ≥800 dynes.sec.cm-5 despite treatment with two or more specific PAH therapies
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 9.1
    E.1.2Level LLT
    E.1.2Classification code 10064911
    E.1.2Term Pulmonary arterial hypertension
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    • To evaluate the efficacy of QTI571 compared to placebo as measured by the change in 6-minute walk distance (6MWD) from baseline to 24-weeks
    E.2.2Secondary objectives of the trial
    • To evaluate the time to clinical worsening (TTCW), defined as all cause mortality, overnight hospitalization for worsening PAH (established by external adjudication committee), worsening of WHO functional class or a drop in 6MWD by 15% during 24 weeks of treatment with QTI571 as compared to placebo
    • To assess changes in health-related quality of life after 24 weeks of treatment (using CAMPHOR) with QTI571 compared with placebo
    • To assess the safety and tolerability of QTI571
    • To evaluate change in pulmonary hemodynamics from baseline in patients after 24 weeks of treatment with QTI571 as compared to placebo
    • To assess change in Borg dyspnea score during 6MWT, monthly, with QTI571 as compared to placebo.
    • To assess the pharmacokinetics of QTI571 and the potential for interaction of QTI571 on sildenafil and bosentan
    • To assess the pharmacogenetics of QTI571
    • To assess the use of different possible definitions of time TTCW as a measure of efficacy in treatment of PAH
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1) Male or female 18 years of age or older
    2) A current diagnosis of Pulmonary Arterial Hypertension according to the Dana Point 2008 Meeting: WHO Diagnostic Group I, idiopathic or heritable (familial or sporadic) PAH, PAH associated with collagen vascular disease including systemic sclerosis, rheumatoid arthritis, mixed connective tissue diseases, and overlap syndrome. PAH associated systemic sclerosis, PAH following one year repair of congenital heart defect (ASD, VSD or PDA), or PAH associated with diet therapies or other drugs
    3) A PVR ≥800 dynes.sec.cm-5 despite treatment with two or more specific PAH therapies, including endothelin receptor antagonists (ERA), phosphodiesterase 5 inhibitors (PDE5), or subcutaneous, inhaled, intravenous or oral prostacyclin analogues for ≥ 3 months. Background therapy doses must be stable for ≥ 30 days except for warfarin and prostacyclin analogues ( ≥ 30 days but doses can vary even within the month before enrollment)
    4) WHO Functional Class II-IV. For WHO Functional Class IV, one of the 2 or more specific PAH therapies must be an inhaled, subcutaneous, intravenous or oral prostacyclin analogue, unless the subject has been shown to be intolerant of prostacyclin analogues.
    5) 6MWD ≥ 150 meters and ≤ 450 meters at screening. Distances of two consecutive 6MWTs should be within 15% of one another.
    6) Ability to provide written informed consent by the patient or a legal guardian
    E.4Principal exclusion criteria
    1. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant. UNLESS they are
    a. women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner
    b. women whose partners have been sterilized by vasectomy or other means
    c. two birth control methods.
    2. pregnant or nursing (lactating) women,
    3. have previously received treatment with imatinib
    4. in treatment with chronic nitric oxide therapy
    5. with a diagnosis of pre-existing severe lung disease including parasitic diseases affecting lungs, congenital abnormalities of the lungs, thorax or diaphragm or bronchial asthma that may significantly contribute to severity of PAH in the opinion of the investigator
    6. with a pulmonary capillary wedge pressure > 15 mm Hg to rule out PAH secondary to left ventricular dysfunction If pulmonary capillary wedge pressure is not attainable,
    then a left atrial pressure measurement may be used in its place
    7. with a diagnosis of pulmonary artery or vein stenosis
    8. with other diagnosis of PAH in WHO Diagnostic Group 1 or 1' are excluded including congenital systemic to pulmonary shunts (large, small that are not surgically repaired), portal hypertension, HIV infection, hereditary hemorrhagic telangiectasia, hemoglobinopathies, veno-occlusive disease)
    9. With a diagnosis of PAH associated with: venous hypertension (WHO Diagnostic
    Group II, including LVEF < 45%), hypoxia (WHO Diagnostic Group III), chronic
    pulmonary thromboembolic disease (WHO Diagnostic Group IV) or other
    miscellaneous causes (WHO Diagnostic Class V, which includes sarcoidosis,
    histiocytosis X, lymphangiomatosis, compression of pulmonary vessels, glycogen
    storage disease, Gaucher’s disease, myeloproliferative disorders).
    9. with thrombocytopenia < 50 x109/L
    10. with a history of left heart failure in the past 3 months
    11. with ucontrolled systemic arterial hypertension, systolic > 160 mmHg or diastolic >90 mmHg
    12. with hemoglobin < 100 g/L
    13. with deficiencies of blood coagulation [for details, please report to the protocol]
    14. with disseminated intravascular coagulation
    15. with evidence of major bleeding or intracranial hemorrhage
    16. with a history of elevated intracranial pressure
    17. with a history of latent bleeding risk [for details, please report to the protocol]
    18. with a history of moderate or greater hepatic insufficiency transaminase levels for details, please report to the protocol]
    19. with a history of renal insufficiency
    20. previous therapeutic radiation of lungs or mediastinum
    21. with a history of sickle cell anemia
    22. with a QTcF > 450 msec for males and > 470 msec for females at screening and baseline in the absence of right bundle branch block.
    23. with a history of ventricular tachycardia, ventricular fibrillation or ventricular flutter
    24. having a syncope in the 3 months prior to the screening visit
    25. with a history of Torsades de Pointes
    26. with a history of long QT syndrome
    27. having undergone atrial septostomy in the 3 months prior to the screening visit
    28. having undergone radiofrequency catheter ablation for atrial or sinus arrhythmias in the 3 months prior to screening visit
    29. with an advanced, severe, or unstable disease of any type that may interfere with the primary and secondary endpoint evaluations
    30. with a history of immunodeficiency diseases, including HIV
    31. with a known hypersensitivity to QTI571 or drugs similar to the study drug
    32. with a disability that may prevent the patient from completing all study requirements
    33. with a life expectancy of 6 months or less
    34. having used other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer
    35. with a history of malignancy of any organ system, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases
    36. With a diagnosis of Hepatitis B or C
    37. With a history of alcohol abuse within 6 months of screening
    38. With a history of illicit drug abuse within 6 months of screening
    39. Male subjects must be using two acceptable methods of contraception, (e.g
    spermicidal gel plus condom) for the entire duration of the study, up to the Study
    Completion visit, and refrain from fathering a child in the three months following
    the last study drug administration. Periodic abstinence and withdrawal are not
    acceptable methods of contraception.
    40. Patients with a diagnosis of systemic sclerosis, with the exception of those who can provide results from a pulmonary function test conducted within the 6 months
    preceding enrollment, showing total lung capacity(TLC)> 70% If TLC ≤ 70%, a chest CT showing minimal lung parenchymal involvement must be produced
    Patients who fail to meet all inclusion/exclusion criteria may be re-screened. All re-screened patients must be assigned a new subject number.
    E.5 End points
    E.5.1Primary end point(s)
    • 6MWD – a marker of exercise tolerance (the distance walked in 6 minutes during a 6-minute walk test according to ATS guidelines)
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned7
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA29
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years2
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero Information not present in EudraCT
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) Information not present in EudraCT
    F.1.1.3Newborns (0-27 days) Information not present in EudraCT
    F.1.1.4Infants and toddlers (28 days-23 months) Information not present in EudraCT
    F.1.1.5Children (2-11years) Information not present in EudraCT
    F.1.1.6Adolescents (12-17 years) Information not present in EudraCT
    F.1.2Adults (18-64 years) Yes
    F.1.3Elderly (>=65 years) Yes
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state40
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 100
    F.4.2.2In the whole clinical trial 200
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2009-07-09
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2009-08-13
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2011-05-12
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2023 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands